These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31904703)

  • 1. A Classifier to Predict Viral Control After Antiretroviral Treatment Interruption in Chronic HIV-1-Infected Patients.
    Fehér C; Plana M; Crespo Guardo A; Climent N; Leal L; Ugarte A; Fernández I; Etcheverry MF; Gatell JM; Sánchez-Palomino S; García F; Aloy P
    J Acquir Immune Defic Syndr; 2020 Apr; 83(5):479-485. PubMed ID: 31904703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
    Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
    J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A therapeutic HIV-1 vaccine enhances anti-HIV-1 immune responses in patients under highly active antiretroviral therapy.
    Tung FY; Tung JK; Pallikkuth S; Pahwa S; Fischl MA
    Vaccine; 2016 Apr; 34(19):2225-32. PubMed ID: 27002500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.
    Pollard RB; Rockstroh JK; Pantaleo G; Asmuth DM; Peters B; Lazzarin A; Garcia F; Ellefsen K; Podzamczer D; van Lunzen J; Arastéh K; Schürmann D; Clotet B; Hardy WD; Mitsuyasu R; Moyle G; Plettenberg A; Fisher M; Fätkenheuer G; Fischl M; Taiwo B; Baksaas I; Jolliffe D; Persson S; Jelmert O; Hovden AO; Sommerfelt MA; Wendel-Hansen V; Sørensen B
    Lancet Infect Dis; 2014 Apr; 14(4):291-300. PubMed ID: 24525316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy.
    Gandhi RT; O'Neill D; Bosch RJ; Chan ES; Bucy RP; Shopis J; Baglyos L; Adams E; Fox L; Purdue L; Marshak A; Flynn T; Masih R; Schock B; Mildvan D; Schlesinger SJ; Marovich MA; Bhardwaj N; Jacobson JM;
    Vaccine; 2009 Oct; 27(43):6088-94. PubMed ID: 19450647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-Mediated Immune Predictors of Vaccine Effect on Viral Load and CD4 Count in a Phase 2 Therapeutic HIV-1 Vaccine Clinical Trial.
    Huang Y; Pantaleo G; Tapia G; Sanchez B; Zhang L; Trondsen M; Hovden AO; Pollard R; Rockstroh J; Ökvist M; Sommerfelt MA
    EBioMedicine; 2017 Oct; 24():195-204. PubMed ID: 28970080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postvaccination C-Reactive Protein and C5/gp41
    Huang Y; Zhang L; Jolliffe D; Sanchez B; Stjernholm G; Jelmert Ø; Ökvist M; Sommerfelt MA
    AIDS Res Hum Retroviruses; 2018 Mar; 34(3):307-313. PubMed ID: 29297230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Activation and HIV-Specific CD8(+) T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers.
    Ganesh A; Lemongello D; Lee E; Peterson J; McLaughlin BE; Ferre AL; Gillespie GM; Fuchs D; Deeks SG; Hunt PW; Price RW; Spudich SS; Shacklett BL
    AIDS Res Hum Retroviruses; 2016 Aug; 32(8):791-800. PubMed ID: 27019338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case for preART-adjusted endpoints in HIV therapeutic vaccine trials.
    Huang Y; Zhang L; Jolliffe D; Hovden AO; Ökvist M; Pantaleo G; Sommerfelt MA
    Vaccine; 2016 Mar; 34(10):1282-8. PubMed ID: 26826543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.
    Alatrakchi N; Duvivier C; Costagliola D; Samri A; Marcelin AG; Kamkamidze G; Astriti M; Agher R; Calvez V; Autran B; Katlama C
    AIDS; 2005 Jan; 19(1):25-33. PubMed ID: 15627030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption.
    Barqasho B; Nowak P; Tjernlund A; Kinloch S; Goh LE; Lampe F; Fisher M; Andersson J; Sönnerborg A;
    HIV Med; 2009 Feb; 10(2):94-102. PubMed ID: 19200172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.
    Leal L; Couto E; Sánchez-Palomino S; Climent N; Fernández I; Miralles L; Romero Y; González T; Maleno MJ; Paño B; Pich J; Nicolau C; Gatell JM; Plana M; García F;
    Front Immunol; 2021; 12():767370. PubMed ID: 34858423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption.
    Rockstroh JK; Asmuth D; Pantaleo G; Clotet B; Podzamczer D; van Lunzen J; Arastéh K; Mitsuyasu R; Peters B; Silvia N; Jolliffe D; Ökvist M; Krogsgaard K; Sommerfelt MA
    PLoS One; 2019; 14(1):e0210965. PubMed ID: 30699178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load.
    Lévy Y; Thiébaut R; Montes M; Lacabaratz C; Sloan L; King B; Pérusat S; Harrod C; Cobb A; Roberts LK; Surenaud M; Boucherie C; Zurawski S; Delaugerre C; Richert L; Chêne G; Banchereau J; Palucka K
    Eur J Immunol; 2014 Sep; 44(9):2802-10. PubMed ID: 25042008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV potency of T-cell responses elicited by dendritic cell therapeutic vaccination.
    Surenaud M; Montes M; Lindestam Arlehamn CS; Sette A; Banchereau J; Palucka K; Lelièvre JD; Lacabaratz C; Lévy Y
    PLoS Pathog; 2019 Sep; 15(9):e1008011. PubMed ID: 31498845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of polymorphisms in the HCP5 and HLA-C, and ZNRD1 genes on HIV viral load.
    Thørner LW; Erikstrup C; Harritshøj LH; Larsen MH; Kronborg G; Pedersen C; Larsen CS; Pedersen G; Gerstoft J; Obel N; Ullum H
    Infect Genet Evol; 2016 Jul; 41():185-190. PubMed ID: 27083073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
    Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
    Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.
    Papasavvas E; Foulkes A; Yin X; Joseph J; Ross B; Azzoni L; Kostman JR; Mounzer K; Shull J; Montaner LJ
    Immunology; 2015 Jul; 145(3):380-90. PubMed ID: 25684333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy.
    Nicholson JK; Browning SW; Hengel RL; Lew E; Gallagher LE; Rimland D; McDougal JS
    J Acquir Immune Defic Syndr; 2001 Jun; 27(2):105-15. PubMed ID: 11404531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.